Explore cutting-edge Parkinson's disease research with Novotech CRO's disease report. Learn about new treatments, clinical trials, and future innovations in Parkinson's disease care.
Parkinson's disease, the second most common neurodegenerative disorder, predominantly affects individuals over 65, with global cases expected to double by 2030. Over 8.5 million people lived with the disease in 2019, resulting in 329,000 deaths. The Asia-Pacific region, led by China, bears the highest burden, followed by the U.S. and European nations like Germany, Italy, and the UK. This growing prevalence highlights the urgent need for innovative treatments, driving a dynamic clinical trial landscape focused on disease-modifying therapies and advanced drug development.
The treatment landscape for Parkinson's disease follows global and regional protocols, with Levodopa as the primary therapy for motor symptoms, often combined with COMT or MAO-B inhibitors. Dopamine agonists, anticholinergics, and emerging therapies like adenosine inhibitors address specific needs. In the United States, approved treatments such as Carbidopa/Levodopa are recommended for initial therapy. European and Asian regions largely align with WHO-approved protocols, ensuring consistency in managing the disease globally. These strategies aim to improve the quality of life and manage the growing global burden of Parkinson's disease effectively.
Building on these established treatment strategies, the global clinical trial landscape has become increasingly active in pursuing innovative therapies for Parkinson's disease. Since 2019, the biotech and biopharma industry has initiated over 750 clinical trials for Parkinson's disease worldwide. Asia-Pacific leads in trial activity, driven by Mainland China, while North America follows, with the United States as the primary contributor. Europe also plays a significant role, led by the United Kingdom, Russia, and Spain, with Israel spearheading efforts in other regions. European trials excel in patient recruitment through multi-country collaboration. They provide broader access and leverage experienced trial sites. This highlights a global effort to advance Parkinson's research and develop novel therapies.
The treatment landscape for Parkinson's disease is evolving with a wide range of therapeutic approaches aimed at addressing the disease's complexities. Established companies like Abbott and AbbVie are advancing small molecules, medical devices, and ultrasound-based techniques. Meanwhile, ongoing Phase III trials by Amgen and BeiGene are focused on small molecules and proteins, with early-stage research exploring innovative approaches such as cell and stem cell therapies and adeno-associated virus (AAV)-based treatments. These efforts highlight the industry's dedication to improving patient outcomes through cutting-edge solutions.
Innovative strategies are also targeting core mechanisms of Parkinson's disease, such as alpha-synuclein buildup and neuroinflammation. Gene therapies aim to correct genetic mutations, while advanced Deep Brain Stimulation (DBS) techniques offer personalized symptom management. Stem cell and neural progenitor therapies hold potential for regenerating dopamine neurons, while emerging treatments like fecal microbiota transplantation (FMT) target gut health to reduce systemic inflammation. Together, these advancements demonstrate a global commitment to revolutionizing Parkinson's disease treatment and improving the quality of life for patients worldwide.
Novotech, a global clinical Contract Research Organization (CRO), collaborates with biotech firms to accelerate advanced therapeutics development across all phases. Novotech has experience with over 5,000 clinical projects, offering a wide range of services including laboratories, Phase I facilities, and regulatory expertise. Recognized for its contributions, Novotech has received the Frost &Sullivan 2024 Global Biotech CRO Award, 2024 Employer of Choice, 2024 Great Place to Work in the US, 2024 Brandon Hall Gold Award, CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006.
Discover more about the global clinical trial landscape for Parkinson’s disease by downloading our comprehensive disease report.